Physicians' Academy for Cardiovascular Education

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

Rethinking responsibilities in the prevention and management of cardiometabolic disease

10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

Dialogue on how to overcome clinical inertia with regard to SGLT2i

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2i: Overview of recent trials and guideline recommendations

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME

Introduction on tackling cardiorenal risk in diabetes

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME

CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD

3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
5 Things a cardiologist needs to know about GLP-1RA

Which patients to consider for GLP-1RA?

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME

The role of GLP-1 receptor agonists in CVD prevention

10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME

Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes

10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD

Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools

10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

DKD and CV risk: What is the potential of targeting GLP-1?

10' education - June 16, 2020 - Prof. Erik Stroes, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Rethinking responsibilities in the prevention and management of cardiometabolic disease

10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD
Prof. Stephan Jacob shares his thoughts about the prevention and management of T2DM and cardiometabolic disease.

Prof. Stephan Jacob shares his thoughts about the prevention and management of T2DM and cardiometabolic disease.

What is the effect of low-dose aspirin on dementia risk in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage
 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

No improvement of dementia outcomes with aspirin in T2DM patients

News - Nov. 16, 2021

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

E-learning Teaming up to tackle cardiorenal risk in diabetes

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Managing patients with diabetes requires a team approach of physicians in primary care, nephrologists, cardiologists and diabetologists. In this e-learning course, the discussants present a case of a patient with diabetes and comorbidities that shows the complexity of management of such a patient.

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?

Watch the entire symposium on teaming up to tackle cardiorenal risk in diabetes - The role of SGLT2i: How to overcome clinical inertia?

Dialogue on how to overcome clinical inertia with regard to SGLT2i

Lecture 3 out of 3

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
As part of a series on tackling cardiorenal risk in diabetes, prof. Davies and prof. Marx state that current use of SGLT2 inhibitors is low and discuss how to overcome this.

As part of a series on tackling cardiorenal risk in diabetes, prof. Davies and prof. Marx state that current use of SGLT2 inhibitors is low and discuss how to overcome this.

SGLT2i: Overview of recent trials and guideline recommendations

Lecture 2 out of 3

10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME
This presentation by prof. Marx is the second part of a series on tackling cardiorenal risk in patients with diabetes. He provides an overview of clinical trials with SGLT2 inhibitors and current recommendations in guidelines.

This presentation by prof. Marx is the second part of a series on tackling cardiorenal risk in patients with diabetes. He provides an overview of clinical trials with SGLT2 inhibitors and current recommendations in guidelines.

Introduction on tackling cardiorenal risk in diabetes

Lecture 1 out of 3

10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME
Watch the first part of a series on tackling cardiorenal risk in patients with diabetes by teaming up. Prof. Davies introduces the topic and presents a case.

Watch the first part of a series on tackling cardiorenal risk in patients with diabetes by teaming up. Prof. Davies introduces the topic and presents a case.

RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy is NOT the Only Option

Faculty: George L. Bakris, MD, Biff F. Palmer, MD

Oct. 10, 2021

View this accredited e-learning program with a focus on heart failure at our partner website ReachMD, a leading online learning platform for physicians and other healthcare professionals

Reduced cardiac adipose tissue by GLP-1RA in T2DM

News - Oct. 4, 2021

EASD 2021 Cardiac adipose tissue measured by CT was reduced by treatment with liraglutide compared to placebo in patients with T2DM, but this reduction was dependent on changes in weight loss.

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

EASD 2021 This secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline albuminuria in patients with CKD, with and without T2DM.

Wide distribution of 10-year and lifetime CV risk in patients with diabetes

News - Oct. 1, 2021

EASD 2021 There is a wide distribution of 10-year and lifetime CV risk in diabetes patients with and without a history of CVD. Use of SGLT2 inhibitors and GLP-1RAs was low in all groups.